Northside Capital Management LLC Takes Position in Intuitive Surgical, Inc. $ISRG

Northside Capital Management LLC acquired a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,683 shares of the medical equipment provider’s stock, valued at approximately $669,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Annex Advisory Services LLC grew its position in shares of Intuitive Surgical by 37.4% during the 2nd quarter. Annex Advisory Services LLC now owns 90,943 shares of the medical equipment provider’s stock valued at $36,166,000 after purchasing an additional 24,750 shares in the last quarter. Tema ETFs LLC raised its position in shares of Intuitive Surgical by 28.8% in the second quarter. Tema ETFs LLC now owns 9,704 shares of the medical equipment provider’s stock worth $3,859,000 after buying an additional 2,170 shares in the last quarter. Fiduciary Financial Group LLC raised its position in shares of Intuitive Surgical by 6.1% in the second quarter. Fiduciary Financial Group LLC now owns 972 shares of the medical equipment provider’s stock worth $387,000 after buying an additional 56 shares in the last quarter. Doliver Advisors LP boosted its stake in Intuitive Surgical by 22.9% during the second quarter. Doliver Advisors LP now owns 2,699 shares of the medical equipment provider’s stock valued at $1,073,000 after buying an additional 503 shares during the period. Finally, Generali Investments Management Co LLC boosted its stake in Intuitive Surgical by 2.5% during the second quarter. Generali Investments Management Co LLC now owns 10,066 shares of the medical equipment provider’s stock valued at $4,003,000 after buying an additional 242 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 2.0%

ISRG opened at $401.23 on Wednesday. The business’s fifty day simple moving average is $392.47 and its 200 day simple moving average is $443.35. Intuitive Surgical, Inc. has a 52 week low of $328.57 and a 52 week high of $603.88. The stock has a market cap of $141.75 billion, a PE ratio of 45.96, a P/E/G ratio of 2.84 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The firm had revenue of $2.89 billion during the quarter, compared to analyst estimates of $2.83 billion. During the same quarter in the previous year, the company posted $1.81 earnings per share. The company’s revenue was up 18.4% compared to the same quarter last year. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Insider Activity

In related news, Director Amy L. Ladd sold 400 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $379.00, for a total transaction of $151,600.00. Following the transaction, the director directly owned 251 shares of the company’s stock, valued at approximately $95,129. This trade represents a 61.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the sale, the executive vice president owned 5,320 shares of the company’s stock, valued at $2,016,280. The trade was a 6.99% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 7,106 shares of company stock worth $2,949,518. 0.60% of the stock is currently owned by insiders.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical’s second-quarter results exceeded expectations: revenue rose 18.4% year over year to $2.89 billion, while EPS reached $2.80 versus the $2.48 consensus estimate. Higher margins, continued adoption of its da Vinci and Ion platforms, and long-term demand for robotic-assisted surgery support the bullish case. Intuitive Surgical Just Beat Earnings
• Positive Sentiment: A bullish investor cited Intuitive Surgical’s potential once-per-decade hardware replacement cycle and approximately $8.6 billion cash position, arguing that the more than 30% year-to-date decline could create an attractive long-term entry point. The Number One Reason I Keep Buying Intuitive Surgical
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with a “Moderate Buy” consensus and an average price target of $509.02. However, several firms recently lowered their targets, reflecting greater caution after the earnings report.
• Neutral Sentiment: Reported short interest was zero shares, implying no measurable short-selling pressure. The figure appears unusual and may reflect incomplete or unreliable data rather than a meaningful market signal.
• Negative Sentiment: Despite the earnings beat, investors remain concerned about slowing domestic procedure growth and whether the company’s roughly 46 P/E adequately reflects its growth prospects. Those concerns have contributed to the stock’s recent weakness. Intuitive Surgical Earnings and Valuation Analysis
• Negative Sentiment: Director Amy L. Ladd sold 472 shares across August 10–11, reducing her holdings by a substantial percentage, while EVP Gary Loeb sold 400 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their significance as a discretionary bearish signal but may still weigh modestly on sentiment.

Analyst Ratings Changes

Several research firms recently commented on ISRG. Barclays set a $651.00 target price on Intuitive Surgical and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Wall Street Zen upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Stifel Nicolaus cut their price objective on Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating for the company in a report on Friday, July 17th. Royal Bank Of Canada decreased their price objective on shares of Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $483.00 target price (down from $577.00) on shares of Intuitive Surgical in a research note on Friday, July 17th. Twenty analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $509.02.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.